Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients

Vaccine

Volumn 25, Issue 37-38, 2007, Pages 6793-6806

  Schlaphoff, Verena ^a   Klade, Christoph S ^b   Jilma, Bernd ^c   Jelovcan, Sandra B ^b   Cornberg, Markus ^a   Tauber, Erich ^a   Manns, Michael P ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INTERCELL AG   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD8 T cell memory; Hepatitis C; Vaccination

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CD45RA ANTIGEN; EPITOPE; GAMMA INTERFERON; HEPATITIS C VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; PEPTIDE; POLYARGININE; SYNTHETIC PEPTIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SYNTHESIS; EFFECTOR CELL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MORPHOLOGICAL TRAIT; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN RESTRICTION;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEALTH; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PHENOTYPE; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES;

EID: 34548210447     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.026     Document Type: Article

References (61)

1. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 9 (2006) 1350-1359
2. Kim W.R. The burden of hepatitis C in the United States. Hepatology 36 5 Suppl 1 (2002) S30-S34
3. Kim W.R., Brown Jr. R.S., Terrault N.A., and El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 36 1 (2002) 227-242
4. Wong J.B. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 24 7 (2006) 661-672
5. Ahlen G., Nystrom J., Pult I., Frelin L., Hultgren C., and Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 192 12 (2005) 2112-2116
6. Chen J.Y., and Li F. Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J Gastroenterol 12 48 (2006) 7774-7778
7. Encke J., Findeklee J., Geib J., Pfaff E., and Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 142 2 (2005) 362-369
8. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24 20 (2006) 4343-4353
9. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12 2 (2006) 190-197
10. Forns X., Payette P.J., Ma X., Satterfield W., Eder G., Mushahwar I.K., et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32 3 (2000) 618-625
11. Pancholi P., Perkus M., Tricoche N., Liu Q., and Prince A.M. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77 1 (2003) 382-390
12. Nevens F., Roskams T., Van Vlierberghe H., Horsmans Y., Sprengers D., Elewaut A., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 5 (2003) 1289-1296
13. Jeong S.H., Qiao M., Nascimbeni M., Hu Z., Rehermann B., Murthy K., et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 78 13 (2004) 6995-7003
14. Langhans B., Braunschweiger I., Nischalke H.D., Nattermann J., Sauerbruch T., and Spengler U. Presentation of the HCV-derived lipopeptide LP20-44 by dendritic cells enhances function of in vitro-generated CD4+ T cells via up-regulation of TLR2. Vaccine 24 16 (2006) 3066-3075
15. Langhans B., Schweitzer S., Nischalke H.D., Braunschweiger I., Sauerbruch T., and Spengler U. Hepatitis C virus-derived lipopeptides differentially induce epitope-specific immune responses in vitro. J Infect Dis 189 2 (2004) 248-253
16. Gruener N.H., Lechner F., Jung M.C., Diepolder H., Gerlach T., Lauer G., et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 75 12 (2001) 5550-5558
17. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127 3 (2004) 924-936
18. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 6 (2002) 3447-3458
19. Vezys V., Masopust D., Kemball C.C., Barber D.L., O'Mara L.A., Larsen C.P., et al. Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med 203 10 (2006) 2263-2269
20. Carrasco J., Godelaine D., Van Pel A., Boon T., and van der Bruggen P. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood 108 9 (2006) 2897-2905
21. Wills M.R., Carmichael A.J., Weekes M.P., Mynard K., Okecha G., Hicks R., et al. Human virus-specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. J Immunol 162 12 (1999) 7080-7087
22. Butcher E.C., and Picker L.J. Lymphocyte homing and homeostasis. Science 272 5258 (1996) 60-66
23. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 6754 (1999) 708-712
24. van Leeuwen E.M., van Buul J.D., Remmerswaal E.B., Hordijk P.L., ten Berge I.J., and van Lier R.A. Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation. Int Immunol 17 6 (2005) 713-719
25. Hamann D., Roos M.T., and van Lier R.A. Faces and phases of human CD8 T-cell development. Immunol Today 20 4 (1999) 177-180
26. Lanzavecchia A., and Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 17 3 (2005) 326-332
27. Sallusto F., Langenkamp A., Geginat J., and Lanzavecchia A. Functional subsets of memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol 251 (2000) 167-171
28. Amanna I.J., Slifka M.K., and Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 211 (2006) 320-337
29. Caccamo N., Meraviglia S., La Mendola C., Guggino G., Dieli F., and Salerno A. Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol 177 3 (2006) 1780-1785
30. Hueman M.T., Stojadinovic A., Storrer C.E., Dehqanzada Z.A., Gurney J.M., Shriver C.D., et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 56 2 (2007) 135-146
31. Monsurro V., Wang E., Yamano Y., Migueles S.A., Panelli M.C., Smith K., et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104 7 (2004) 1970-1978
32. Powell Jr. D.J., and Rosenberg S.A. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 27 1 (2004) 36-47
33. Wedemeyer H., Berg T., Manns M.P., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Induction of TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. J. Hepatol. 42 (2005) 9-10
34. Lucas M., Vargas-Cuero A.L., Lauer G.M., Barnes E., Willberg C.B., Semmo N., et al. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol 172 3 (2004) 1744-1753
35. van Leeuwen E.M., de Bree G.J., ten Berge I.J., and van Lier R.A. Human virus-specific CD8+ T cells: diversity specialists. Immunol Rev 211 (2006) 225-235
36. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L., et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8 4 (2002) 379-385
37. Chen G., Shankar P., Lange C., Valdez H., Skolnik P.R., Wu L., et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 98 1 (2001) 156-164
38. Papagno L., Appay V., Sutton J., Rostron T., Gillespie G.M., Ogg G.S., et al. Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors. Clin Exp Immunol 130 3 (2002) 509-517
39. Gamadia L.E., Rentenaar R.J., Baars P.A., Remmerswaal E.B., Surachno S., Weel J.F., et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 98 3 (2001) 754-761
40. Hislop A.D., Gudgeon N.H., Callan M.F., Fazou C., Hasegawa H., Salmon M., et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 167 4 (2001) 2019-2029
41. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 9 (2000) 1499-1512
42. Rock M.T., Yoder S.M., Wright P.F., Talbot T.R., Edwards K.M., and Crowe Jr. J.E. Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization. J Immunol 174 6 (2005) 3757-3764
43. Betts M.R., Exley B., Price D.A., Bansal A., Camacho Z.T., Teaberry V., et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 102 12 (2005) 4512-4517
44. Perambakam S., Hallmeyer S., Reddy S., Mahmud N., Bressler L., DeChristopher P., et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 55 9 (2006) 1033-1042
45. Yagi H., Hashizume H., Horibe T., Yoshinari Y., Hata M., Ohshima A., et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 66 20 (2006) 10136-10144
46. Hafalla J.C., Rai U., Morrot A., Bernal-Rubio D., Zavala F., and Rodriguez A. Priming of CD8+ T cell responses following immunization with heat-killed Plasmodium sporozoites. Eur J Immunol 36 5 (2006) 1179-1186
47. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137
48. Dunne P.J., Faint J.M., Gudgeon N.H., Fletcher J.M., Plunkett F.J., Soares M.V., et al. Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 100 3 (2002) 933-940
49. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 3 (2003) 225-234
50. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76 12 (2002) 6104-6113
51. Wiegand J., Cornberg M., Aslan N., Schlaphoff V., Sarrazin C., Kubitschke A., et al. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antivir Ther. 12 3 (2007) 303-316
52. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 3 (2005) 215-229
53. Luhrs P., Schmidt W., Kutil R., Buschle M., Wagner S.N., Stingl G., et al. Induction of specific immune responses by polycation-based vaccines. J Immunol 169 9 (2002) 5217-5226
54. Mattner F., Fleitmann J.K., Lingnau K., Schmidt W., Egyed A., Fritz J., et al. Vaccination with poly-l-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 62 5 (2002) 1477-1480
55. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 3 (1996) 706-714
56. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 5 (2000) 578-582
57. Wedemeyer H., Mizukoshi E., Davis A.R., Bennink J.R., and Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 75 23 (2001) 11392-11400
58. Urbani S., Amadei B., Fisicaro P., Pilli M., Missale G., Bertoletti A., et al. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 201 5 (2005) 675-680
59. Cornberg M., Chen A.T., Wilkinson L.A., Brehm M.A., Kim S.K., Calcagno C., et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 116 5 (2006) 1443-1456
60. Selin L.K., Cornberg M., Brehm M.A., Kim S.K., Calcagno C., Ghersi D., et al. CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol 16 5 (2004) 335-347
61. Sarrazin C., Wohnsland A., Wedemeyer H., Burger V., Zauner W., Tauber E., et al. Quasispecies evolution in chronic hepatitis C patients after immunization with the therapeutic vaccine IC41. J. Hepatol. 44 (2006) S166-166